Primary assessment of medicines for expected migrastatic potential with holographic incoherent quantitative phase imaging

Solid tumor metastases cause most cancer-related deaths. The prevention of their occurrence misses suitable anti-metastases medicines newly labeled as migrastatics. The first indication of migrastatics potential is based on an inhibition of in vitro enhanced migration of tumor cell lines. Therefore,...

Descripción completa

Detalles Bibliográficos
Autores principales: Šuráňová, Markéta, Ďuriš, Miroslav, Štenglová Netíková, Irena, Brábek, Jan, Horák, Tomáš, Jůzová, Veronika, Chmelík, Radim, Veselý, Pavel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Optica Publishing Group 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278600/
https://www.ncbi.nlm.nih.gov/pubmed/37342686
http://dx.doi.org/10.1364/BOE.488630
_version_ 1785060519847133184
author Šuráňová, Markéta
Ďuriš, Miroslav
Štenglová Netíková, Irena
Brábek, Jan
Horák, Tomáš
Jůzová, Veronika
Chmelík, Radim
Veselý, Pavel
author_facet Šuráňová, Markéta
Ďuriš, Miroslav
Štenglová Netíková, Irena
Brábek, Jan
Horák, Tomáš
Jůzová, Veronika
Chmelík, Radim
Veselý, Pavel
author_sort Šuráňová, Markéta
collection PubMed
description Solid tumor metastases cause most cancer-related deaths. The prevention of their occurrence misses suitable anti-metastases medicines newly labeled as migrastatics. The first indication of migrastatics potential is based on an inhibition of in vitro enhanced migration of tumor cell lines. Therefore, we decided to develop a rapid test for qualifying the expected migrastatic potential of some drugs for repurposing. The chosen Q-PHASE holographic microscope provides reliable multifield time-lapse recording and simultaneous analysis of the cell morphology, migration, and growth. The results of the pilot assessment of the migrastatic potential exerted by the chosen medicines on selected cell lines are presented.
format Online
Article
Text
id pubmed-10278600
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Optica Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-102786002023-06-20 Primary assessment of medicines for expected migrastatic potential with holographic incoherent quantitative phase imaging Šuráňová, Markéta Ďuriš, Miroslav Štenglová Netíková, Irena Brábek, Jan Horák, Tomáš Jůzová, Veronika Chmelík, Radim Veselý, Pavel Biomed Opt Express Article Solid tumor metastases cause most cancer-related deaths. The prevention of their occurrence misses suitable anti-metastases medicines newly labeled as migrastatics. The first indication of migrastatics potential is based on an inhibition of in vitro enhanced migration of tumor cell lines. Therefore, we decided to develop a rapid test for qualifying the expected migrastatic potential of some drugs for repurposing. The chosen Q-PHASE holographic microscope provides reliable multifield time-lapse recording and simultaneous analysis of the cell morphology, migration, and growth. The results of the pilot assessment of the migrastatic potential exerted by the chosen medicines on selected cell lines are presented. Optica Publishing Group 2023-05-16 /pmc/articles/PMC10278600/ /pubmed/37342686 http://dx.doi.org/10.1364/BOE.488630 Text en Published by Optica Publishing Group under the terms of the Creative Commons Attribution 4.0 License. Further distribution of this work must maintain attribution to the author(s) and the published article’s title, journal citation, and DOI. https://creativecommons.org/licenses/by/4.0/ https://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Šuráňová, Markéta
Ďuriš, Miroslav
Štenglová Netíková, Irena
Brábek, Jan
Horák, Tomáš
Jůzová, Veronika
Chmelík, Radim
Veselý, Pavel
Primary assessment of medicines for expected migrastatic potential with holographic incoherent quantitative phase imaging
title Primary assessment of medicines for expected migrastatic potential with holographic incoherent quantitative phase imaging
title_full Primary assessment of medicines for expected migrastatic potential with holographic incoherent quantitative phase imaging
title_fullStr Primary assessment of medicines for expected migrastatic potential with holographic incoherent quantitative phase imaging
title_full_unstemmed Primary assessment of medicines for expected migrastatic potential with holographic incoherent quantitative phase imaging
title_short Primary assessment of medicines for expected migrastatic potential with holographic incoherent quantitative phase imaging
title_sort primary assessment of medicines for expected migrastatic potential with holographic incoherent quantitative phase imaging
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278600/
https://www.ncbi.nlm.nih.gov/pubmed/37342686
http://dx.doi.org/10.1364/BOE.488630
work_keys_str_mv AT suranovamarketa primaryassessmentofmedicinesforexpectedmigrastaticpotentialwithholographicincoherentquantitativephaseimaging
AT durismiroslav primaryassessmentofmedicinesforexpectedmigrastaticpotentialwithholographicincoherentquantitativephaseimaging
AT stenglovanetikovairena primaryassessmentofmedicinesforexpectedmigrastaticpotentialwithholographicincoherentquantitativephaseimaging
AT brabekjan primaryassessmentofmedicinesforexpectedmigrastaticpotentialwithholographicincoherentquantitativephaseimaging
AT horaktomas primaryassessmentofmedicinesforexpectedmigrastaticpotentialwithholographicincoherentquantitativephaseimaging
AT juzovaveronika primaryassessmentofmedicinesforexpectedmigrastaticpotentialwithholographicincoherentquantitativephaseimaging
AT chmelikradim primaryassessmentofmedicinesforexpectedmigrastaticpotentialwithholographicincoherentquantitativephaseimaging
AT veselypavel primaryassessmentofmedicinesforexpectedmigrastaticpotentialwithholographicincoherentquantitativephaseimaging

Ejemplares similares